Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Settles Dispute over Lab Sale


Rosetta Genomics said this week that it has settled a dispute with Sanra Laboratories in connection with Rosetta’s sale of Parkway Laboratories to Sanra in 2009.

As reported by Gene Silencing News, Rosetta bought Parkway for $2.9 million in 2008 in order to pick up the expertise and infrastructure needed to begin marketing its line of microRNA-based diagnostics (GSN 6/12/2008).

Rosetta used Parkway’s CLIA certification to establish its own CLIA-certified lab where it performs its miRNA tests, and sold off Parkway to Sanra the next year for up to $2.5 million, payable over six years as a fixed percentage of revenues (GSN 5/21/2009).

This week, Rosetta said that Sanra has agreed to use its “best efforts” to pay Rosetta $625,000, in addition to all sums previously paid, to meet obligations under a stock-purchase deal inked in conjunction with the Parkway sale.

Additional terms of the settlement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.